12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Forxiga dapagliflozin regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Forxiga dapagliflozin from Bristol-Myers and partner AstraZeneca as an add-on to metformin or insulin to treat Type II diabetes. Forxiga as an add-on to metformin is recommended according to current NICE guidelines for dipeptidyl peptidase-4 (DPP-4) inhibitors. The FAD reverses preliminary draft guidance released in January in which NICE said it...

Read the full 310 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >